Galderma Group AG Non-GAAP EPS of $2.34, net sales of $3.13B
Seeking Alpha ·
Galderma Group AG press release ( GALDY ): 1H Non-GAAP EPS of $2.34, marking a 68.50% YoY increase . Core EBITDA increased 42.80% year-over-year to $0.80B, while c ore EBITDA margin expanded by 328 basis points to reach 25.60% . Raised full-year net sales guidance to 19.00%–21.00% growth . Q1 2026 Confirms Multi-Engine Growth Acceleration At Galderma Group AG (Rating Upgrade) Jazz, AstraZeneca, Astellas: Foreign Healthcare's strongest Quant picks Seeking Alpha’s Quant Rating on Galderma Group AG Historical earnings data for Galderma Group AG Dividend scorecard for Galderma Group AG
AI 시장 분석
Galderma Group (GALDY) reported 1H Non-GAAP EPS of $2.34, surging 68.50% year-over-year, while core EBITDA also increased by 42.80% to $0.80 billion. Driven by this strong performance, the company raised its full-year net sales growth guidance from 19.00% to 21.00%. This is raising market expectations for accelerated multi-engine growth and stimulating positive investment sentiment within the healthcare sector. Investors should pay attention to robust margin expansion and guidance upgrades, and consider the possibility of further valuation rerating.
상승 영향
- Biotech — Galderma's 1H EPS surged 68.50% and full-year sales guidance was raised to 19-21%, increasing the investment appeal of the overall healthcare sector.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
495 participants
Related News
- Banner projects mid-single-digit 2026 loan growth while expecting Bank of the Pacific deal to close in Q3
- Cass Information Systems Non-GAAP EPS of $0.71 misses by $0.01, revenue of $49.94M misses by $1.08M
- Carter Bank & Trust reports Q2 results
- Yelp giving ChatGPT access to customer reviews, business information -- report
- BNP Paribas SA reports Q2 results
- Esquire Financial targets ~5.45% Day 1 combined NIM as Signature merger set to close August 1, 2026
